C. Lydon

发表

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

S. Digumarthy, J. Roth, M. Mino‐Kenudson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute

J. Meyerhardt, D. Glazer, M. Taplin, 2020, Journal of the National Cancer Institute.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer

A. Iafrate, A. Shaw, B. Yeap, 2018, Clinical Cancer Research.

Safety and Efficacy of PD‐1 Inhibitors Among HIV‐Positive Patients With Non–Small Cell Lung Cancer

D. Costa, F. Marty, M. Cheng, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.

P. Jänne, G. Freeman, D. Jackman, 2014 .

Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma.

P. Jänne, E. V. Van Allen, J. Heymach, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

T. Forshew, M. Nishino, M. Awad, 2020, Journal for ImmunoTherapy of Cancer.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

P. Tamayo, C. Paweletz, Kwok-Kin Wong, 2018, Nature Medicine.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

N. Schultz, M. Ladanyi, D. Zelterman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

P. Jänne, G. Freeman, F. Hodi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive Biomarkers and Personalized Medicine Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

B. Yeap, M. Nishino, L. Sholl, 2013 .

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

P. Jänne, D. Jackman, S. Rodig, 2015, Clinical Cancer Research.

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

S. Carter, L. Garraway, E. V. Van Allen, 2015, Cancer Immunology Research.

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome

H. Hatabu, M. Nishino, M. Rabin, 2019, The oncologist.

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

C. Paweletz, P. Jänne, L. Sholl, 2016, Cancer discovery.

Five‐Year Survival in EGFR‐Mutant Metastatic Lung Adenocarcinoma Treated with EGFR‐TKIs

P. Jänne, D. Jackman, S. Dahlberg, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study

Carrie Cibulskis, Nikhil Wagle, Steven Joffe, 2017, Genetics in Medicine.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

H. Hatabu, D. Jackman, M. Nishino, 2015, European journal of radiology.

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib

H. Hatabu, M. Nishino, M. Awad, 2020, Journal of thoracic imaging.

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

Jeanne Shen, P. Jänne, B. Yeap, 2013, Clinical Cancer Research.

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

H. Hatabu, M. Nishino, M. Awad, 2020, European journal of radiology open.

Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome

P. Jänne, F. Hodi, H. Hatabu, 2017, Clinical Cancer Research.

Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers.

A. Redig, P. Jänne, Emily S. Chambers, 2016 .

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

D. Jackman, M. Rabin, J. Jacobson, 2017, Journal of oncology practice.

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.

D. Jackman, M. Rabin, J. Jacobson, 2017 .

Molecular markers of metastatic disease in KRAS mutant lung adenocarcinoma.

E. V. Van Allen, P. Janne, D. Barbie, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome

H. Hatabu, M. Nishino, M. Rabin, 2019, European journal of radiology open.

Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.

M. Mino‐Kenudson, A. Shaw, M. Hellmann, 2018 .

Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.

P. Jänne, N. Lindeman, L. Sholl, 2014 .

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

T. Forshew, M. Nishino, M. Awad, 2021, Journal for ImmunoTherapy of Cancer.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

P. Jänne, F. Hodi, D. Jackman, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer

P. Jänne, C. Voena, R. Chiarle, 2017, Oncotarget.